The pharmaceutical giant, Biogenis, is seeking FDA approval for an experimental treatment for early Alzheimer’s disease. They announced that a new analysis showed a significant reduction in clinical decline in one trial. Results for some patients in another study support those findings, as well. According to their data, patients who received aducanumab experienced significant benefits on measures of cognition and function, including memory, orientation and language.
Nearly 5.8 million people in the United States currently live with Alzheimer’s. The disease is the sixth leading cause of death in the United States.